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A ketogenic diet suppresses seizures in mice
through adenosine A1 receptors
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A ketogenic diet (KD) is a high-fat, low-carbohydrate metabolic regimen; its effectiveness in the treatment
of refractory epilepsy suggests that the mechanisms underlying its anticonvulsive effects differ from those
targeted by conventional antiepileptic drugs. Recently, KD and analogous metabolic strategies have shown
therapeutic promise in other neurologic disorders, such as reducing brain injury, pain, and inflammation.
Here, we have shown that KD can reduce seizures in mice by increasing activation of adenosine A1 receptors
(A1Rs). When transgenic mice with spontaneous seizures caused by deficiency in adenosine metabolism or
signaling were fed KD, seizures were nearly abolished if mice had intact A1Rs, were reduced if mice expressed
reduced A1Rs, and were unaltered if mice lacked A1Rs. Seizures were restored by injecting either glucose (metabolic reversal) or an A1R antagonist (pharmacologic reversal). Western blot analysis demonstrated that the
KD reduced adenosine kinase, the major adenosine-metabolizing enzyme. Importantly, hippocampal tissue
resected from patients with medically intractable epilepsy demonstrated increased adenosine kinase. We therefore conclude that adenosine deficiency may be relevant to human epilepsy and that KD can reduce seizures by
increasing A1R-mediated inhibition.
Introduction
A ketogenic diet (KD) is an alternative metabolic treatment for
epilepsy, and multiple retrospective and prospective studies confirm its clinical benefits (1, 2). The high-fat, low-carbohydrate
composition of a KD forces ketone- rather than glucose-based
metabolism, but it is not known how this shift leads to anticonvulsant consequences. Primary applications of KD therapy include
pediatric and medically refractory epilepsy; its use is increasing
globally, and clinical benefits are similar across cultures and age
groups (1, 2). Despite its success, side effects and requisite strict
compliance have limited widespread use of KD, and a diet-based
approach is often considered as a last resort. Better understanding of the mechanisms involved in the anticonvulsant actions of a
KD could lead to development of pharmacological strategies that
take advantage of beneficial aspects and limit problems associated with diet therapy.
Adenosine acting at adenosine A1 receptors (A1Rs) is a logical
candidate for the effects of KD therapy (3). Adenosine is well-established as a powerful anticonvulsant (4), and endogenous adenosine acting at A1Rs is an important seizure-control mechanism (5).
Moreover, deletion of A1Rs and increased adenosine clearance by
elevated adenosine kinase (ADK) both cause spontaneous intrahippocampal electrographic seizures (6) and increase the brain’s susceptibility to injury (7). Conversely, therapeutic adenosine augmentation is highly effective in controlling seizures (8). Adenosine is the
core of ATP, a key molecule in basic biochemistry and a ligand at its
own family of G protein–coupled cell surface receptors. Thus, adenosine is a homeostatic bioenergetic network regulator involved in
metabolism and ongoing neuronal activity and is well-positioned
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to translate metabolic changes into altered brain activity. Using 3
lines of transgenic mice that all exhibit electrographic seizures as a
result of deficient adenosine signaling (6), we present here what we
believe to be the first direct evidence that adenosine acting at A1Rs
contributes to the therapeutic effects of KDs.
Results and Discussion
A1R activation suppresses seizures. In line with our previous demonstration (6), A1R+/– mice, A1R–/– mice, and Adk-Tg mice (based on
expression of a ubiquitously expressed Adk transgene on an Adknull background) maintained on a control diet (CD) experienced
regular electrographic hippocampal seizures consistent with deficient adenosine/A1R signaling (Figure 1). Seizure frequency and
duration were similar between Adk-Tg and A1R–/– mice and significantly lower in A1R+/– mice (but still elevated above WT; Table 1).
Behavioral (clinical) seizures were never observed in the mutants,
and electrographic seizures were never observed in the WT group.
To quantify the effects of KD, WT and transgenic mice were
fed CD or KD. At 3 weeks, KD nearly abolished seizures in Adk-Tg
mice and significantly reduced the duration of remaining seizures (Table 1 and Figure 1). If KD suppresses seizures in Adk-Tg
mice by elevating adenosine in brain, we predicted that its seizure-suppressing potential would be reduced in A 1R +/– mice,
which have only 50% of this receptor and lowered sensitivity to
adenosine (9). As expected, KD-fed A1R+/– mice experienced a
significant, but lesser (approximately 50%), reduction in seizure
frequency, although seizure duration was not changed compared with CD-fed A1R+/– mice (Table 1). We further predicted
that spontaneous seizures in A1R–/– mice would be resistant to
the beneficial effects of KD if its protective mechanism involves
activation of A 1Rs. Indeed, KD was completely ineffective in
affecting seizures in A1R–/– mice. These findings demonstrate
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compared with WT mice. There
was no difference in βHB levels
between genotypes when mice
were fed CD (WT, 0.48 ± 0.09 mM;
A1R–/–, 0.60 ± 0.09 mM; n = 5 per
group, P > 0.05), and there was
no evidence for inadequate or
decreased ketones in A1R–/– mice
fed KD for 3 weeks. βHB levels
were elevated similarly and significantly in both genotypes in
KD- versus CD-fed mice (WT,
P < 0.001; A1R–/–, P < 0.002); overall, KD-fed A 1R –/– mice demonstrated a nonsignificant trend
toward higher βHB levels compared with KD-fed WT mice (WT,
1.38 ± 0.15 mM; A1R–/–, 1.96 ± 0.29
mM; n = 5 per group, P > 0.05).
Figure 1
KD reduces ADK expression. AmbiSeizure suppression by KD depends on A1R activation. Representative EEG recordings from the CA3 of
WT and transgenic mice reflect seizure distribution over a 1-hour time span (top traces) and individual ent adenosine in brain is regulated
seizures at higher resolution (1 minute; bottom traces). Asterisks in top traces denote the individual largely by ADK (10). Whereas overseizures chosen. Beginning and end of seizures are marked by vertical arrows. Traces from CD-fed ani- expression of ADK (causing ademals showed baseline seizure activity in all mutants and lack of seizures in WT. KD almost completely nosine deficiency) has been linked
abolished seizures in Adk-Tg mice; rare seizures were of reduced duration, as shown. KD reduced to seizures (6), reduced expression
seizure activity in A1R+/– mice, had no effect in A1R–/– mice. Treatment with glucose or DPCPX reversed of ADK (thus increasing adeno
KD effects. See Table 1 for quantitation.
sine) renders the brain less susceptible to seizures (6) and might be
involved in an endogenous protecthat KD suppresses seizures caused by adenosine deficiency tive mechanism of the brain in response to stress or injury (10). We
(Adk-Tg) or reduced adenosine signaling (A 1R +/–), but has no therefore hypothesized that metabolic stress imposed by KD might
likewise lead to reduction in brain ADK. KD- or CD-fed WT mice
effect in the absence of A1Rs (A1R–/–).
Seizures are restored with glucose or A1R blocker treatment. To deter- were sacrificed at 3 and 4 weeks of feeding, corresponding to the
mine the extent to which the reduced frequency of spontaneous time span of seizure analysis above. Western blot showed that this
seizures in Adk-Tg and A1R+/– mice was specifically the result of the key adenosine-regulating enzyme was downregulated significantly
low-carbohydrate nature of KD, we injected glucose into KD-fed in the KD group (Figure 2), which suggests a possible mechanism
mice of each genotype. In Adk-Tg and A1R+/– mice, which displayed for KD’s seizure suppression.
reduced seizures after KD, glucose injection increased seizure frequency significantly within 30–90 minutes; in Adk-Tg mice, the
increase did not quite reestablish the baseline CD-fed seizure pheTable 1
notype (Table 1 and Figure 1).
Seizure frequency and duration
The loss of KD-induced seizure suppression in A1R–/– mice,
combined with the reduced efficacy of KD in A1R+/– compared
CD
KD
KD plus
KD plus
with Adk-Tg mice, is indicative of seizure suppression via a mechglucose
DPCPX
anism involving A1Rs. To test this further, we injected a nonFrequency (seizures/h)
convulsive dose of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX;
WT
0
0
0
0
+/–
1 mg/kg), an A1R-selective antagonist. In Adk-Tg and A1R mice,
Adk-Tg
4.8 ± 0.4
0.6 ± 0.2A
4.1 ± 0.2B,C
4.9 ± 0.5C
DPCPX restored seizure frequency to control levels, whereas
A1R+/–
3.8 ± 0.7
1.8 ± 0.4A
3.4 ± 0.3C
3.9 ± 0.7C
it had no significant effect in WT or A1R–/– mice (Figure 1 and
–/–
A1R
5.3 ± 0.6
5.1 ± 0.6
5.2 ± 0.5
4.9 ± 0.5
Table 1). DPCPX in KD-fed Adk-Tg mice increased seizure duraDuration (s)
tion significantly compared with both CD and KD conditions;
WT
0
0
0
0
however, it did not change seizure duration in A1R+/– mice, which
Adk-Tg 26.8 ± 3.3
14.4 ± 4.0A
18.6 ± 2.0B,D 37.6 ± 4.3A,C
suggests that its effect on duration depended on the relative
A1R+/–
16.4 ± 1.6
15.9 ± 4.2
16.2 ± 2.1
16.4 ± 2.2
abundance of A1Rs. As expected, DPCPX had no effect on seiA1R–/–
27.9 ± 2.4
29.3 ± 2.9
31.2 ± 4.9
29.9 ± 3.1
–/–
zures in A1R mice. These data, coupled with the lack of KD
efficacy in A1R–/– mice, demonstrated that A1Rs are a molecular
Mice were maintained on CD or KD for 3 weeks. KD reduced spontaneous seizures in Adk-Tg and A1R+/– mice and was ineffective in
target whereby KD reduces ictogenesis in vivo.
A1R–/– mice; glucose (2 g/kg i.p.) or DPCPX (1 mg/kg i.p.) reversed its
WT and A1R–/– mice have similar metabolic responses. To confirm that
anti-ictogenic effects. Values are mean ± SD. n = 10 (CD, KD); 5 (KD
–/–
A1R mice experienced a similar metabolic response to KD, we
plus glucose, KD plus DPCPX). AP < 0.001, BP < 0.05 vs. CD.
CP < 0.001, DP < 0.05 vs. KD alone.
measured the plasma level of β-hydroxybutyrate (βHB) in A1R–/–
2680
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Figure 2
KD leads to downregulation of ADK. (A) Representative Western blot
from brain extracts of WT mice fed CD or KD for 3 and 4 weeks. Note
the 2 different splice variants of ADK in the ADK-reactive bands. Antitubulin immunoreactivity was used to normalize for equal loading. Lanes
were run on the same gel but were noncontiguous (white line). (B) Brain
ADK from mice fed CD or KD for 3–4 weeks, expressed relative to CD
(n = 4 per group). Data are mean ± SEM. **P < 0.01 vs. CD.

ADK overexpression in human epilepsy. We have demonstrated previously that astrogliosis, ADK overexpression, and resulting adenosine deficiency are implicated in seizure generation in rodent
models of epilepsy (6, 10). Therefore, reconstitution of normal
adenosine signaling by KD might be of therapeutic value for epileptic patients with refractory temporal lobe epilepsy (TLE). To
investigate whether adenosine dysfunction is likewise implicated
in the pathology of human epilepsy, we studied the expression
of ADK in hippocampus of patients with hippocampal sclerosis
(HS) and histologically normal human hippocampus. ADK was
upregulated within specific hippocampal regions in HS specimens
compared with control hippocampus (Figure 3, A–D). Abundant
ADK-immunopositive cells with typical astroglial morphology
were observed in areas with prominent gliosis in all HS specimens;
double-labeling confirmed ADK expression in glial fibrillary acidic protein–positive (GFAP-positive) reactive astrocytes (Figure 3,
B and D). Western blot analysis confirmed a greater than 3-fold
increase in ADK levels in hippocampus of TLE patients (Figure 3,
E and F), which suggests that adenosine deficiency could contribute to the epileptic phenotype in those patients.
Using transgenic mice and complementary pharmacology, we
demonstrated that KD-induced seizure control was dependent on
A1Rs: KD virtually abolished seizures in Adk-Tg mice (with reduced
endogenous adenosine and intact A1Rs), reduced seizures partially
but significantly in A1R+/– mice, and had no effects in A1R–/– mice
or in the presence of A1R blockade. We showed overexpression of
ADK (which should reduce A1R activation) in human epilepsy and
KD-induced reduction of ADK in mouse brain, thus providing a
mechanism for KD-induced increase in adenosine and anticonvulsant effects of KD via A1Rs. Whereas altered adenosinergic signaling might not be the underlying cause for seizures in all epilepsies,
adenosine has stopped seizures in every seizure model tested to
date, including models of pharmacoresistant epilepsy. Thus, no
matter the cause of the seizure, adenosine can help to resolve
it, provided — as shown here — that A1Rs are present. Subclinical, brief electrographic seizure events (undetectable with scalp
electrodes), as exhibited in all 3 strains of transgenic mice in the
present study, are now increasingly recognized and likely play an
important role in early epileptogenesis (11).
The Journal of Clinical Investigation

Acute reversal of seizure suppression by glucose confirmed the
specificity of KD’s metabolic effects and comported with clinical
observations and animal studies highlighting the importance of low
glucose to the effects of KD (12). Indeed, we recently demonstrated in
vitro that metabolic consequences of KD — reduced extracellular glucose and increased intracellular ATP — produce A1R-dependent inhibition of cornu ammonis region 3 (CA3) pyramidal cells (3). Of interest, glucose-induced seizure reversal in Adk-Tg mice was not complete
(which indicates that the specific enzymatic activity of ADK might
have been increased based on rapid glucose-dependent restoration
of the energy charge), although ADK levels were still quantitatively
reduced (Figure 2). Additional mechanisms might also contribute to
KD-induced seizure suppression: in vitro studies demonstrated direct
acute effects of ketones (13, 14), although the relative importance of
these mechanisms to the chronic in vivo effects of KD administration in humans remains to be determined.
When relating these findings to human epilepsy, we found
that brain tissue resected from humans with intractable epilepsy
showed increased ADK — and therefore likely a relative adenosine
deficiency. Previously, adenosine deficiency has been demonstrated
directly in microdialysis samples from epileptogenic hippocampus
in human patients with TLE (15). These results and our current
data indicate that alteration of adenosine signaling is relevant to
human epilepsy. Specifically, at least some forms of human epilepsy replicate key features of our adenosine-deficient model,
increasing the translational potential of these results. Together,
these data delineate a clinically relevant relationship among KD,
adenosine, and epilepsy, which could lead to less-restrictive diets,
alternate pharmaceutical approaches, and broader applications of
metabolic strategies to different medical conditions.
Methods
Animals. All animal procedures were approved by the Legacy Institutional
Animal Care and Use Committee. Adk-Tg mice are based on expression of
a ubiquitously expressed Adk transgene on an Adk-null background, leading to brain-wide ADK overexpression (6). A1R+/– and A1R–/– mice lack 1
or both A1R alleles (9). All animals were maintained on a C57BL/6 background. Male mice were fed either CD or KD (product no. F3666; Bioserv)
ad libitum for 4 weeks (n = 10 per genotype). To reverse KD effects, animals
received i.p. injection of either glucose in water (30% w/v; 2 g/kg) or DPCPX
(1 mg/kg; 2 ml/kg in 20% DMSO [w/v]).
EEG studies. Bipolar, coated stainless-steel electrodes were implanted into the
right CA3, and monopolar reference and ground electrodes were affixed above
cortex and cerebellum, as described previously (6). 24 hours after implantation,
we recorded 12 hours of continuous EEG from each animal using a Nervus
EEG recording system (6). Seizures were defined as high-amplitude rhythmic
discharges (repetitive spikes, spike-and-wave discharges, slow waves) lasting
at least 5 seconds. After 12 hours, each animal received glucose or DPCPX,
and EEG monitoring resumed for another 12 hours. All EEG recordings were
performed at 3–4 weeks of diet treatment and within 48 hours of electrode
implantation to exclude chronic reactions to the electrodes.
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Figure 3
ADK immunoreactivity in hippocampus of control and TLE patients with medial temporal HS. (A–D) Sections were counterstained with hematoxylin. Shown are representative CA1 (A and B) and hilus (C and D) from the same sample. (A and C) Control hippocampus showed weak ADK
immunoreactivity. Histologically normal surgical hippocampus displayed an immunoreactivity pattern similar to that in control autopsy hippocampus (not shown). (B and D) The HS specimen demonstrated increased ADK expression in both residual pyramidal and hilar neurons (arrows
and B, top inset) and in reactive astrocytes (arrowheads and B, bottom inset). Insets in D show expression of ADK (red) in a reactive astrocyte
(GFAP, green). Scale bars: 160 μm (A and B); 80 μm (C and D); 40 μm (A, inset, and B, top inset); 15 μm (B, bottom inset, and D, insets). (E and
F) Western blot analysis of ADK of total homogenates from control autopsy hippocampus and HS specimens. (E) Representative immunoblots.
(F) Densitometric data, expressed relative to optical density of β-actin (n = 5 per group). Data are mean ± SEM. *P < 0.05 vs. control.

βHB measurement. Mice were deeply anesthetized and blood collected
via cardiac puncture into EDTA-containing syringes. After centrifugation,
plasma was assayed for βHB with a Precision Xtra monitor and ketone test
strips (Abbott Laboratories).
Human material. Human specimens were a gift from J.C. Baajen (University of Amsterdam Academic Medical Center and VU University Medical Center, Amsterdam, The Netherlands). Written informed consent was
obtained from patients or their guardians, and brain tissue was handled
in a manner compliant with the guidelines and approval of AMC’s Medical Ethics Committee (MEC; University of Amsterdam, Amsterdam, The
Netherlands). Patients underwent resection for refractory epilepsy and
had predominantly medically intractable complex partial seizures. We
examined 11 surgical epilepsy specimens: 6 with HS (mean age, 26.4 years;
range, 18–42 years) and 5 without HS (mean age, 29.5 years; range, 18–41
years; with a focal lesion not involving hippocampus proper and no appreciable neuronal loss or reactive gliosis observed in hippocampus). Normal-appearing control hippocampus was obtained at autopsy from adults
(mean age, 31 years; range, 18–35 years) without a history of seizures or
other neurological diseases within 12 hours of death. Tissue was fixed,
paraffin embedded, sectioned (6 μm), and processed for hematoxylin and
eosin and immunocytochemistry for GFAP (monoclonal mouse, 1:4,000;
DAKO) and ADK (polyclonal rabbit, 1:500) (6). Single- and double-label
immunocytochemistry was performed as described previously (16).
Western blotting. Freshly frozen histologically normal autopsy hippocampus and HS samples (n = 5 per group) were homogenized. 30 μg protein
was separated by standard gel electrophoresis, transferred, and incubated
overnight in buffer (20 mM Tris, 150 mM NaCl, 0.1% Tween, 5% nonfat dry
milk, pH 7.5) containing the primary ADK antibody (1:5,000). Preparation
2682
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and analysis of Western blots were performed as described previously (16).
Mouse brain was processed similarly using 50 μg protein derived from WT
whole brain extracts (n = 4; CD and KD). ADK levels were normalized to
internal standards and reported relative to control. Densitometry was performed using ImageJ (NIH).
Statistics. Seizure data were analyzed using StatView for Windows (version 5.0.1; SAS Institute Inc.), reported as mean ± SD from 5 hours of
blinded recording from each animal and condition, and analyzed using
1-way ANOVA followed by Bonferroni/Dunn multiple test for individual
means. Data for ADK and ketone quantification were reported as mean ±
SEM and analyzed using 2-tailed Student’s t test. A P value of 0.05 or less
was considered significant.
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